Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study

被引:45
作者
Buyken, Anette E.
von Eckardstein, Arnold
Schulte, Helmut
Cullen, Paul
Assmann, Gerd
机构
[1] Univ Munster, Leibniz Inst Arteriosclerosis Res, D-48149 Munster, Germany
[2] Univ Zurich, Inst Clin Chem, CH-8006 Zurich, Switzerland
来源
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION | 2007年 / 14卷 / 02期
关键词
diabetes mellitus; coronary heart disease; coronary risk assessment;
D O I
10.1097/HJR.0b013e3280142037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background American and European consensus opinions recommend that diabetes mellitus be regarded as a 'coronary risk equivalent, that is, as conferring the same risk of myocardial infarction as established coronary heart disease. We examined if this holds true for men in the Prospective Cardiovascular Munster Study (PROCAM). Design We conducted a single-centre, prospective, epidemiological study, calculating risk using the PROCAM calculator, which takes diabetes mellitus into account, in men at work in public authorities and large companies in the region of Munster, Germany. Participants Five thousand, three hundred and eighty-nine men aged 35-65 years at recruitment participated, 3778 of whom were normoglycaemic, 1205 of whom displayed impaired fasting glycaemia, and 406 of whom suffered from diabetes mellitus. Coronary events (fatal or nonfatal myocardial infarction, sudden coronary death) occurring within 10 years of unbroken follow-up were assessed. Results Of men with diabetes mellitus 13.3% suffered a coronary event within 10 years, compared with 7.3% of men with impaired fasting glycaemia, and 5.3% of normoglycaemic men. Using the PROCAM risk calculator, only 26.5% of the men with diabetes mellitus were calculated to have a 10-year coronary event risk at or above the threshold of 20% (high risk) regarded as being equivalent to the risk conferred by established coronary heart disease. Eight percent of men with impaired fasting glycaemia and 5.5% of normoglycaemic men were at high risk. The positive predictive value of a high-risk estimate was 35% in men with diabetes, 32% in men with impaired fasting glycaemia, and 31% in normoglycaemic men. Conclusion In PROCAM, less than a third of men with diabetes were classified as being at high risk of coronary events. It is therefore incorrect to regard the presence of diabetes mellitus as a coronary risk equivalent.
引用
收藏
页码:230 / 236
页数:7
相关论文
共 23 条
  • [1] American Diabetes Association, 1998, DIABETES CARE S1, V21, ps5
  • [2] [Anonymous], 2002, JAMA
  • [3] Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study
    Assmann, G
    Cullen, P
    Schulte, H
    [J]. CIRCULATION, 2002, 105 (03) : 310 - 315
  • [4] WHY IS DIABETES-MELLITUS A STRONGER RISK FACTOR FOR FATAL ISCHEMIC-HEART-DISEASE IN WOMEN THAN IN MEN - THE RANCHO-BERNARDO STUDY
    BARRETTCONNOR, EL
    COHN, BA
    WINGARD, DL
    EDELSTEIN, SL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (05): : 627 - 631
  • [5] Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease - 10-year follow-up of the Hoorn Study
    Becker, A
    Bos, G
    de Vegt, F
    Kostense, PJ
    Dekker, JM
    Nijpels, G
    Heine, RJ
    Bouter, LM
    Stehouwer, CDA
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (15) : 1406 - 1413
  • [6] The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men
    Cho, E
    Rimm, EB
    Stampfer, MJ
    Willett, WC
    Hu, FB
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (05) : 954 - 960
  • [7] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [8] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [9] Collins R, 2003, LANCET, V361, P2005
  • [10] Cullen P, 1997, CIRCULATION, V96, P2128